Kestra Medical Technologies Reports 60% Revenue Growth but Increased Net Loss in Latest Quarter

Kestra Medical Technologies, Ltd. reported significant financial developments in its latest 10-Q filing for the quarter ending July 31, 2026. The company generated revenue of $30.97 million, a 60% increase from $19.37 million in the same period last year. This growth was primarily attributed to an increase in the number of patients utilizing its ASSURE® Wearable Cardioverter Defibrillator (WCD) system. Despite the revenue increase, Kestra reported a net loss of $44.09 million, compared to a loss of $25.83 million in the prior year, reflecting a 71% increase in losses driven by higher operating expenses.

Operating expenses for the quarter rose to $55.16 million, up 46% from $37.73 million in the previous year. This increase was largely due to a $14.63 million rise in selling, general, and administrative expenses, which included costs associated with expanding the commercial team and increased personnel expenses. Research and development expenses also increased by 70% to $6.80 million, reflecting ongoing investments in product development and clinical collaborations. The gross profit for the quarter was reported at $17.50 million, nearly doubling from $8.85 million a year earlier, indicating improved cost management and operational efficiencies.

In terms of operational metrics, Kestra's cash and cash equivalents stood at $68.56 million as of July 31, 2026, down from $99.71 million at the end of the previous fiscal year. The company also reported an accumulated deficit of $695.95 million. The total number of common shares outstanding increased to 59.27 million, up from 58.38 million, reflecting ongoing equity financing activities. The company has been actively expanding its commercial presence, with a focus on increasing patient engagement and market penetration for its cardiac recovery solutions.

Strategically, Kestra has made significant moves to bolster its financial position, including a recent $75 million draw from a new term loan facility established in July 2026. This financing is part of a broader strategy to support operational growth and product development. The company has also emphasized its commitment to enhancing its manufacturing capabilities and expanding its market reach, particularly in the U.S. healthcare landscape. Looking ahead, Kestra anticipates that its existing cash reserves, along with revenue generated from operations, will be sufficient to fund its operational needs for at least the next 12 months, although it acknowledges the potential need for additional funding to support its growth initiatives.